69 related articles for article (PubMed ID: 1895553)
1. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Karim A; Kook C; Novotney RL; Zagarella J; Campion J
Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
8. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
9. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
11. The kinetics of aminosidine in renal patients with different degrees of renal failure.
Novarini A; Montanari A; Bruschi G; Rossi E; Borghetti A; Migone L
Clin Nephrol; 1975 Jul; 4(1):23-4. PubMed ID: 1157346
[TBL] [Abstract][Full Text] [Related]
12. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
Cook CS; Karim A; Sollman P
Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ofloxacin in severe chronic renal failure.
Bandai H; Tsubakihara Y; Yamato E; Yokoyama K; Okada N; Nakanishi I; Iida N
Clin Ther; 1989; 11(2):210-8. PubMed ID: 2736567
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois B; Mallein R; Rondelet J; Lussignol M
Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
Aso R; Ohashi K; Katoh T; Ogata H
Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
Aronoff GR
J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S974-6. PubMed ID: 6085387
[TBL] [Abstract][Full Text] [Related]
17. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of norfloxacin in chronic renal failure.
Arrigo G; Cavaliere G; D'Amico G; Passarella E; Broccali G
Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Johnston A; Henry JA; Warrington SJ; Hamer NA
Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]